Drug treatment of refractory status epilepticus

• Published in: Revue neurologique Vol. 165; no. 4; pp. 373 - 379
• Main Authors: Rossetti, A O, Santoli, F
• Format: Journal Article
• Language: French
• Published: France 01.04.2009
• Subjects: Anticonvulsants - therapeutic use; Barbiturates - therapeutic use; Drug Resistance; Humans; Hypnotics and Sedatives - therapeutic use; Midazolam - therapeutic use; Propofol - therapeutic use; Status Epilepticus - drug therapy; Status Epilepticus - epidemiology
• ISSN: 0035-3787
• DOI: 10.1016/j.neurol.2008.12.003

Status epilepticus (SE) refractory to benzodiazepines and other antiepileptic agents is managed with intravenous anesthetic compounds, such as thiopental, propofol or midazolam. These drugs display quite different pharmacodynamic and pharmacokinetic properties, but have not been prospectively compared to date. Their use is clearly advocated for the treatment of generalized convulsive SE, whereas partial-complex, or absence SE are generally managed less aggressively, in consideration of their better prognosis. The most important aspect seems to be related to the correct use of these anesthetics in the right context, rather than the choice of one specific compound. An electroencephalographic burst-suppression should be targeted for about 24 hour, before progressive weaning of the dosage under EEG monitoring. If this approach proves unsuccessful, the use of other drugs, including inhalational anesthetics, has been described.